Dengvaxia: Boon for Dengue

Posted on

The recent outbreak of Dengue in Asia has brought forward the threat of mosquito bite into the spotlight again. Dengue is a kind of viral infection caused by mosquito bite, and the disease has now become a threat to about 390 million people, as these many are estimated to be infected each year. This incidence of infection in recent decades has soared and the world has been a witness to a great number of deaths globally. Asia is emerging to be the most impacted region with about 75% of the global burden of dengue.

According to World Health Organization (WHO), the number of the cases in Malaysia, Philippines, Vietnam and India has increased alarmingly, as compared to what it was two years ago. However, there is hope for its effective treatment and cure, as Sanofi Pasteur has successfully developed a vaccine after investing approximately 20 years in R&D. Sanofi Pasteur is the first company to come up with dengue vaccine named as “Dengvaxia”. According to Sanofi, they want to make the drug available to everyone, particularly to the low income countries. For this they have joined hands with a number of International Organizations like World Health Organization (WHO), United Nations Children’s Fund (UNICEF), and Red Cross.

So far, the drug has got market approval in 11 countries, including Mexico, Philippines, Brazil, El Salvador, Costa Rica, Paraguay, Guatemala, Peru, Indonesia, Thailand and Singapore; Mexico is the one to become the first country to license it. The company is now waiting for its approval from the Indian government which may take some more time as the government has asked to conduct more trials before granting permission.

Neil Ferguson, Director of the MRC center for Outbreak Analysis and Modeling at Imperial College London, conducted a study that used the previous data to determine its effect in various settings found out that the vaccine may not work properly in areas where there is low prevalence of dengue; the WHO has thus not recommended countries to implement a national vaccination program using Dengvaxia. Companies like Sun Pharma, Takeda and Butantan Institute, Brazil are also working on dengue vaccine and we can expect a more efficacy from their products.

Insight by:
Megha Khandelwal
Associate Analyst



Global Hemophilia Market

Posted on Updated on

Get Market Intelligence of Hemophilia Market with DelveInsight

The Haemophilia Market is driven by clotting factor concentrates. Besides hemophilia A and B, and those with von Willebrand disease (VWD), is also sometimes treated with clotting factor.

Currently about 20,000 people have hemophilia in the US; about 80% of them have hemophilia A, and 3,000 to 4,000 have hemophilia B. About 400 US babies with hemophilia are born each year. Von Willebrand disease is the most common bleeding disorder, affecting about 1% of the population.

In the Haemophilia world; diseases are cured by factors like Hemophilia A patients use factor VIII (FVIII), Hemophilia B patients use factor IX (FIX) and VWD patients use factor VIII with VWF (VWF/FVIII complex).

Long Acting Treatments haemophillia

The Recombinant hemophilia market is set to take over the market place with the long acting treatments in the major markets; the US, France, Germany, Italy, Spain, UK and Japan by the beginning in the US in 2014 and the European countries (5EU) in 2015. The launch of Biogen Idec and Sobi’s long-acting therapies for hemophilia A and B will affect the position of Baxter, Bayer and Pfizer’s market- leading therapies. These long acting therapies will give a significant increase in sales to the hemophilia market.
Understand Haemophilia Market with our Reports. Get the deeper understanding of the long-acting recombinant factor VIII and factor IX therapies and its impact on the on current treatments for hemophilia A and B and VWD. Global sales forecasting of the Hemophilia Market till 2016 for the individual marketed products. Get access over pipeline drugs, the technology, stage of development, their targets, mechanism of action with our Pipeline reports.

Contact Us at 
Our reports can be customized to include any specific information that you might interested in. Send us an email with your requirements and our team will get back to you instantly.

DelveInsight’s Marketed and Pipeline Reports Going Viral!

Posted on Updated on

If a market is growing enormously, you need to understand what’s nourishing it


DelveInsight Report

DelveInsight has launched its Reports under two brands Pharm Delve and Pharm Insights.

Pharm Delve reports are known for its extensive detailed information of the Marketed drugs– Global Market, API Market & Manufacturers across the US, Europe and Asia specifically China and India and Phase III Pipeline drugs information. These reports provide whole list of companies interested in your business. It gives you the most up to date information on drug marketed data, patent data, upcoming API with lots of potential in market, interested Generic Drug Companies, Active Pharmaceutical Ingredient (API) Manufacturers to determine which companies and therapies are emerging leaders while understanding the market needs.

Pharm Insights covers the pipeline reports. Mechanism of Action Reports launched has become the most known and on demand amongst the clients. The report has highlighted all the under development drugs falling under the specific MOA with the comparative analysis at various stages and therapeutics assessment by monotherapy and combination products and molecule type drug information. The reports have covered each and every detail of the drugs while chemical information and company profile are considered thoroughly.

Five worth Reason for Spending on these Reports

  1. Track your closest Competitors
  2. Identifying potential customers
  3. Prioritizing new drug intermediates to add to the portfolio
  4. Uncovering opportunities Globally
  5. Organic as well as Inorganic Growth

Who can buy these Reports?

  • Pharma Companies
  • Drug Development Companies
  • Generic Manufacturing Companies
  • API Manufacturers
  • Institutions/Universities

 Where to buy?

You can buy these reports from the resellers given : Report Buyer, Report Linker, ASD Media, VPG Market Research, Market Publishers, Bharat Book Bureau and Report stack

About DelveInsight

DelveInsight is a Business consultant and Knowledge Partner and have extensive experience across the value chain of pharmaceutical industry. We provide cutting-edge market and pipeline analysis and API intelligence to the Pharma and Biotech sector, helping clients to quantify market events and evaluate their impact on the valuation of products, portfolios and companies.

At DelveInsight, we believe what we do matters. We are passionate about our work, inspired by the impact it has on our business and our customers. As a team, we believe in winning as one – collaborating to reach shared goals, and developing through challenging and meaningful experiences. The pharmaceuticals market is in its growth stage and we are uniquely positioned to successfully endeavor the dimensions of the fast growing market by providing clear and forthright business recommendations to help clients evaluate potential paths and make vital decisions at all stages of a product’s lifecycle and across multiple business and therapeutic areas.